Evidence map›Paper›PMID 41100186›Full record

ArticleBioinformatics (Oxford, England)2025

IntegrAlign: a comprehensive tool for multi-immunofluorescence panel integration through image alignment.

Leo Hermet, Leo Laoubi, Martial Scavino, Anne-Claire Doffin, Alexia Gazeu, Justine Berthet, Berenice Pillat, Stephanie Tissot, Sylvie Rusakiewicz, Marie-Cécile Michallet and 5 more

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Leo HermetCentre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Lyon, 69008, France.
Leo LaoubiCentre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Lyon, 69008, France.ORCID 0000-0001-9388-4826
Martial ScavinoCentre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Lyon, 69008, France.
Anne-Claire DoffinCentre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Lyon, 69008, France.
Alexia GazeuCentre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Lyon, 69008, France.
Justine BerthetCentre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Lyon, 69008, France.
Berenice PillatCentre Léon Bérard, Lyon, 69008, France.
Stephanie TissotCenter of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital, Lausanne, CH-1011, Switzerland.
Sylvie RusakiewiczCenter of Experimental Therapeutics, Department of Oncology, Lausanne University Hospital, Lausanne, CH-1011, Switzerland.
Marie-Cécile MichalletCentre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Lyon, 69008, France.
Nathalie Bendriss-VermareCentre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Lyon, 69008, France.
Jenny Valladeau-GuilemondCentre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Lyon, 69008, France.
Jean HausserDepartment of Cell and Molecular Biology, Karolinska Institutet, Stockholm, 171 77, Sweden.
Christophe CauxCentre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Lyon, 69008, France.
Margaux HubertCentre Léon Bérard, Centre de Recherche en Cancérologie de Lyon, Univ Lyon, Université Claude Bernard Lyon 1, INSERM U1052, CNRS 5286, Lyon, 69008, France.ORCID 0000-0003-2584-6494

Funding

EFPIAEuropean Union's Horizon 2020 research and innovation programmeFondation ARC pour la Recherche sur le Cancer ARCSIGNIT2023030006402IMMUcanINCa-DGOS 2022-186Innovative Medicines Initiative 2 Joint Undertaking 821558LABEX DEVweCAN ANR-10-LABX-0061Ligue Nationale contre le cancer 399 EL2020.LNCC-CHCLYriCAN+, INCa-DGOS-INSERM-ITMO cancer_18003Région Rhône Alpes RRA18-010792-01-10365SIRIC
6 · The paper itself

Abstract

motivationTyramide-based multiplex-immunofluorescence (mIF) enables the simultaneous analysis of up to seven protein markers on a whole slide, providing a comprehensive approach to study the tumor microenvironment. Integrating multiple mIF panels through image alignment of serial slide significantly expands the number of cell populations analysed in a single space. IntegrAlign was developed to optimize this integration on serial whole slides, enhancing the value and applicability of -mIF for comprehensive spatial analyses and enabling biomarker discovery at scale.

resultsIntegrAlign, leveraging the SimpleITK toolkit, applies a two-step alignment using rigid and B-spline transformations to integrate serial mIF whole slides. Validation on simulated and real datasets demonstrated alignment accuracy below the diameter of a cell nucleus (∼6 µm), outperforming existing methods. This precision enhances spatial analyses by combining extended phenotypic data, supporting novel insights into tissue architecture and cellular interactions. AVAILABILITY AND IMPLEMENTION: IntegrAlign is open-source, implemented in Python, and freely available under the MIT license at https://github.com/CAUXlab/IntegrAlign.

Indexed as

Fluorescent Antibody TechniqueImage Processing, Computer-AssistedSoftwareHumansTumor Microenvironment

Identifiers

PMID41100186
PMCPMC12582367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.